Key Takeaways:
UnitedHealth Group shares surged more than 5% on Thursday, leading the Dow Jones Industrial Average to a fresh all-time high, after Bank of America upgraded the health insurer to "buy" and raised its price target to $450 from $420.
"Incoming data points make it more difficult to believe that the strong Q1 was purely a function of weak flu and storms," Bank of America analysts said in a note, citing expectations of improving margins from more favorable medical cost trends.
The new price target implies roughly 14% upside from UnitedHealth's recent trading level near $396. The stock has rallied about 20% year to date and has more than doubled from its late-March lows, recovering from a prolonged slump driven by elevated medical costs, investigations into billing practices, and a sudden chief executive change last year.
The upgrade comes as UnitedHealth prepares to report second-quarter results in July. Bank of America said recent data points on medical cost trends and insurance utilization suggest a "favorable" setup for the quarter, which could extend the stock's recovery. Higher-than-expected medical costs had weighed on UnitedHealth's results in recent quarters, pressuring margins and dragging the stock to multiyear lows.
The Dow Jones Industrial Average added 850 points on Thursday, closing at an all-time high, with UnitedHealth and Goldman Sachs Group each contributing roughly 5% gains. The broader S&P 500 rose 0.5%, while the tech-heavy Nasdaq added 0.3%, as gains in healthcare and financials offset a broadcom-led pullback in semiconductor stocks.
For UnitedHealth holders, the upgrade signals that Wall Street sees the worst of the medical cost pressure as behind the company. The next catalyst is the second-quarter earnings report, expected in mid-July, which will test whether margin improvement is materializing as analysts anticipate.
This article is for informational purposes only and does not constitute investment advice.
